Pedicle Screw Fusion Faces Maturing Market… But Still Growing

For markets in an phase of maturity — facing the introduction of competing new technologies taking away market share — price reductions are an effort to counterbalance the forces for declining demand. However, in the case of pedicle screw fusion systems in spine surgery, price pressures are acting independently of demand. In essence, there is such demand for spine surgery treatments that, even in the face of new device treatments competitive with pedicle screw fusion, there is growth in procedure and unit volumes such that even a nominal -0.7% CAGR decrease in prices from 2011 to 2020 is associated with a 9% CAGR in the pedicle screw fusion systems market.

In the “short” run (i.e., 5-10 years), this can be sustained, but demand for alternative spine surgery devices will continue to accelerate and prices for pedicle screw systems will be forced to drop more steeply in response.

Below is a graph of pedicle screw fusion system unit volumes against average selling price during the 2010 to 2020 forecast period.

Source: MedMarket Diligence Report #M520: Worldwide Spine Surgery 2010-2020.

Unit volume growth in pedicle screw systems in the face of declining prices and increasing markets for competitive technologies is testimony to the enormous demand for spine surgery solutions to chronic back pain and the other adverse sequellae of spine trauma and disease.

Posted via email from medmarket’s posterous

pedicle screws spinal surgery

Author

PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

View all posts by PatrickDriscoll